American Journal of Epidemiology Vol. 126, No. 3: 492-499
Copyright © 1987 by The Johns Hopkins University School of Hygiene and Public Health
research-article |
HEPATITIS B VIRUS INFECTION IN CHINESE FAMILIES IN HONGKONG
1University Department of Medicine Queen Mary Hospital, Hong Kong
2Department of Pathology, University of Hong Kong Hong Kong
3Department of Obstetrics and Gynecology University of Hong Kong, Hong Kong
4Medical Unit A, Queen Elizabeth Hospital Hong Kong
5Clinical Biochemistry Unit, Queen Mary Hospital Hong Kong
Reprint requests to Dr. Anna Suk-Fong Lok
Lok, A. S-F. (U. Dept. of Medicine, Queen Mary Hospital, Hong Kong), C-L. Lai, P-C. Wu, V. C-W. Wong, E-K. Yeoh, and H-J. Lin. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol 1987;126:492-9.
Between January 1983 and July 1984, 731 family members of 240 hepatitis B surface antigen (HBsAg) carriers were screened for hepatitis B virus markers. The percentage of those who were positive for HBsAg was 28.3 and that for antibody to hepatitis B surface antigen/antibody to hepatitis B core antigen was 43.1. The carrier rate was higher among siblings (53%) and offspring (50.5%) of female carriers, but similar to that of the age-matched general population for spouses (10.8%). Maternal transmission was the most important mode of spread of hepatitis B virus infection within the family. The HBsAg-positive offspring and siblings were clustered within certain families. Intrafamilial spread is important in perpetuating hepatitis B virus infection in Chinese persons. Susceptible family members, especially newborns and other young children of female carriers, should be vaccinated.
carrier state; family; hepatitis B core antigens; hepatitis B surface antigens; hepatitis B virus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Liang How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation Blood, April 2, 2009; 113(14): 3147 - 3153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yeo, T. C. Chan, N. W.Y. Leung, W. Y. Lam, F. K.F. Mo, M. T. Chu, H. L.Y. Chan, E. P. Hui, K. I.K. Lei, T. S.K. Mok, et al. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab J. Clin. Oncol., February 1, 2009; 27(4): 605 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Mackie MD MHSc, J. A. Buxton MBBS MHSc, S. Tadwalkar MD BHSc, and D. M. Patrick MD MHSc Hepatitis B immunization strategies: timing is everything Can. Med. Assoc. J., January 20, 2009; 180(2): 196 - 202. [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. So and P. C. Ng International Perspectives: Neonatology in Hong Kong: 10 Years After the Return of Sovereignty to China NeoReviews, December 1, 2007; 8(12): e513 - e521. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Hutton, D. Tan, S. K. So, and M. L. Brandeau Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B Ann Intern Med, October 2, 2007; 147(7): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Shin, B. L. Park, H. S. Cheong, J.-H. Yoon, Y. J. Kim, and H.-S. Lee SPP1 polymorphisms associated with HBV clearance and HCC occurrence Int. J. Epidemiol., October 1, 2007; 36(5): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yeo, F. K. F. Mo, J. Koh, A. T. C. Chan, T. Leung, P. Hui, L. Chan, A. Tang, J. J. Lee, T. S. K. Mok, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma Ann. Onc., July 1, 2006; 17(7): 1083 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yeo, K. C. Lam, B. Zee, P. S. K. Chan, F. K. F. Mo, W. M. Ho, W. L. Wong, T. W. T. Leung, A. T. C. Chan, B. Ma, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy Ann. Onc., November 1, 2004; 15(11): 1661 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yeo, P. K.S. Chan, W. M. Ho, B. Zee, K. C. Lam, K. I.K. Lei, A. T.C. Chan, T. S.K. Mok, J. J. Lee, T. W.T. Leung, et al. Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy J. Clin. Oncol., March 1, 2004; 22(5): 927 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Kim, H.-S. Lee, J.-H. Yoon, C. Y. Kim, M. H. Park, L. H. Kim, B. L. Park, and H. D. Shin Association of TNF-{alpha} promoter polymorphisms with the clearance of hepatitis B virus infection Hum. Mol. Genet., October 1, 2003; 12(19): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Kawsar and B. Goh Hepatitis B virus infection among Chinese residents in the United Kingdom Sex Transm Inf, June 1, 2002; 78(3): 166 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liang, G. K.K. Lau, and Y. L. Kwong Chemotherapy and Bone Marrow Transplantation for Cancer Patients Who Are Also Chronic Hepatitis B Carriers: A Review of the Problem J. Clin. Oncol., January 1, 1999; 17(1): 394 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. L Lloyd, S. Wong, T. Yu, and T. Wong Mortality Mapping in Hong Kong, 1979-83 and 1984-88: Feasibility Study and the Patterns of Cancers Asia Pac J Public Health, April 1, 1995; 8(2): 66 - 73. [Abstract] [PDF]
|
|